There were 199 press releases posted in the last 24 hours and 172,567 in the last 365 days.

Results announcement for the third quarter 2013

Wednesday 23 October

GSK announces Q3 core EPS growth of16% and dividend of 19p

  • Core EPS 28.9p (+16%) benefiting from operating, financial and long-term cost efficiencies
  • Pharma Vaccines sales flat: US +2%, Europe +5%, Japan +2% offset by EMAP -9%,
  • Consumer Healthcare +4%
  • Fourapprovals in three markets; Tivicay for HIV and FluLaval Q-IV vaccine for flu; Tafinlar for metastatic melanoma; Relvar Ellipta for asthma
  • Q3 dividend of 19p (+6%)
  • Full year 2013 guidance reaffirmed
  • View full Q3 2013 results (PDF)

    More informationincludingincluding CFO interview are available in thequarterly resultssection of this website.